Cardiol Therapeutics Inc. (CRDL)
1.02
0.06 (6.58%)
At close: Apr 14, 2025, 3:59 PM
1.01
-0.98%
After-hours: Apr 14, 2025, 07:26 PM EDT
6.58% (1D)
| Bid | 0.92 |
| Market Cap | 84.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.68M |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -2.83 |
| Forward PE | -3.45 |
| Analyst | Buy |
| Ask | 1.06 |
| Volume | 164,767 |
| Avg. Volume (20D) | 251,542 |
| Open | 0.97 |
| Previous Close | 0.96 |
| Day's Range | 0.95 - 1.02 |
| 52-Week Range | 0.77 - 3.12 |
| Beta | 0.67 |
About CRDL
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respirat...
Sector Healthcare
IPO Date Jan 15, 2019
Employees 18
Stock Exchange NASDAQ
Ticker Symbol CRDL
Website https://www.cardiolrx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CRDL stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 782.35% from the latest price.
Stock Forecasts6 months ago
-6.63%
Cardiol Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
6 months ago
+3.7%
Cardiol Therapeutics shares are trading lower after the company announced a preliminary prospectus for a proposed public offering of common stock, size or amount not disclosed.
